IRIS Reports Q2 Earnings

Improved sales of IRIS International’s in vitro diagnostics products, contributed to the company’s improved gross margins in the second quarter. The Chatsworth-based company reported a net income of $624,000, or $0.03 per diluted share, on revenues of $26.7 million for the second quarter ended June 30. For the same period a year ago, the company reported a net income of $1.0 million, or $0.06 per diluted share, on revenues of $22.3 million. While the improvements in revenue and gross margins in all core business segments reflect a continued improvement in the global hospital spending environment, the positive results were offset by foreign currency fluctuations, according to IRIS.